The anti-EGFR monoclonal antibody cetuximab has been used for many years as first-line or second-line systemic treatment for metastatic and/or recurrent HNSCC alone or in combination with other antineoplastic agents, e.g., cisplatin chemotherapy and 5-FU (EXTREME regimen) (49) or taxane instead of 5-FU (TPExtreme) (50). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.